



BSW Formulary Update – March 2023

New and Updated Shared Care Agreements and Prescribing Guidance

- **NEW - [BSW SCA for Guanfacine for the treatment of ADHD in Adults](#)**. Used in line with NICE NG87 as a third-line option (off-label use) on the advice of a tertiary ADHD service. *Note that an update from BSW lead mental health commissioner is expected to follow soon on the ongoing work around the local commissioning arrangements for patients with ADHD transitioning out of paediatric services and patients seen by private providers.*
- **NEW - [BSW SCA for Stiripentol for Dravet Syndrome in children from 3yrs to adulthood](#)**. Used in line with NICE NG217 and on the advice of a tertiary epilepsy service. *Note that BSW APC recognises stiripentol is an expensive treatment, but patient numbers are expected to be extremely low.*
- **UPDATED – [BSW HRT Formulary treatment options and pathway](#)**. Update includes information on National HRT pre-payment certificate and updated sections on off-license prescribing and useful links.
- **UPDATED – Management of Infection Guidance for primary care. [Full guidance](#) and [QRG for children](#)** amendments made to the Scarlet Fever penicillin allergy antibiotics choice and course duration as per CKS.
- **UPDATED – [SGLT2 Prescribing Information - all indications](#)**. Guidance updated to clarify dosing in renal impairment in line with manufacturers Summaries of Product Characteristics.
- **UPDATED - [DOACs for DVT and PE in adults: local pathways and prescribing criteria](#)**. Updated with clearer introductory statement reminding prescribers that edoxaban should NOT be used as a first line treatment for VTE. Also includes updated contact details for specialist teams and links to local hospital treatment pathways.
- **UPDATED – [BSW Sharps bin guidance](#)**. Updated to include CGM consumables.

Other amendments to BSWformulary

- Sunsense Ultra range discontinued [Formulary \(bswformulary.nhs.uk\)](#)
- Fluocinolone acetonide 0.025% with clioquinol 3% (Synalar C®) discontinued [Formulary \(bswformulary.nhs.uk\)](#)
- Dithranol (Dithrocream®) range discontinued [Formulary \(bswformulary.nhs.uk\)](#)
- DMSO dimethyl sulphoxide bladder installation – moved to non-formulary, no longer used locally. Sodium chondroitin bladder instillation (Uracyst®) discontinued [Formulary \(bswformulary.nhs.uk\)](#)
- Pholcodine-containing cough/cold medicines. Moved to non-formulary following withdrawal from UK market [Formulary \(bswformulary.nhs.uk\)](#)



New additions to BSWformulary

- [TA856](#) Upadacitinib for treating mod to severely active ulcerative colitis – **RED** TLS
- [TA871](#) Eptinezumab for preventing migraine – **RED** TLS

What the BSW CCG formulary team are currently working on

- Working with BSW dermatology teams to update our primary care emollient prescribing guidance for adults.
- Working with BSW diabetes teams to produce local guidance on pharmacological glucose management in adults with Type 2 diabetes.
- Working with renal teams in the region to produce guidance to support the implementation of finerenone for treating CKD in line with NICE TA877 <https://www.nice.org.uk/guidance/ta877>
- Working with BSW specialist teams on a SCA for cinacalcet for primary hyperparathyroidism in adults.
- Working with BSW specialist teams to produce guidance for primary care on the use of relugolix-estradiol-norethisterone acetate for treating uterine fibroids in line with NICE TA832 <https://www.nice.org.uk/guidance/ta832>
- Continuing to review the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net